BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol. 2009;114:457-464. [PMID: 19501389 DOI: 10.1016/j.ygyno.2009.05.022] [Cited by in Crossref: 202] [Cited by in F6Publishing: 201] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Yang X, Wang J, Qu S, Zhang H, Ruan B, Gao Y, Ma B, Wang X, Wu N, Li X, Dou K, Li H. MicroRNA-200a suppresses metastatic potential of side population cells in human hepatocellular carcinoma by decreasing ZEB2. Oncotarget 2015;6:7918-29. [PMID: 25797260 DOI: 10.18632/oncotarget.3486] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
2 Batista L, Gruosso T, Mechta-Grigoriou F. Ovarian cancer emerging subtypes: role of oxidative stress and fibrosis in tumour development and response to treatment. Int J Biochem Cell Biol 2013;45:1092-8. [PMID: 23500525 DOI: 10.1016/j.biocel.2013.03.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
3 Anastasiadou E, Messina E, Sanavia T, Mundo L, Farinella F, Lazzi S, Megiorni F, Ceccarelli S, Pontecorvi P, Marampon F, Di Gioia CRT, Perniola G, Panici PB, Leoncini L, Trivedi P, Lenzi A, Marchese C. MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of β-Catenin and c-Myc. Cells 2021;10:519. [PMID: 33804458 DOI: 10.3390/cells10030519] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Zaravinos A. The Regulatory Role of MicroRNAs in EMT and Cancer. J Oncol. 2015;2015:865816. [PMID: 25883654 DOI: 10.1155/2015/865816] [Cited by in Crossref: 160] [Cited by in F6Publishing: 163] [Article Influence: 22.9] [Reference Citation Analysis]
5 Liu W, Zhang K, Wei P, Hu Y, Peng Y, Fang X, He G, Wu L, Chao M, Wang J. Correlation between miR-200 Family Overexpression and Cancer Prognosis. Dis Markers 2018;2018:6071826. [PMID: 30069274 DOI: 10.1155/2018/6071826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
6 Parizadeh SM, Jafarzadeh-Esfehani R, Ghandehari M, Hasanzadeh M, Parizadeh SMR, Hassanian SM, Rezaei-Kalat A, Aghabozorgi AS, Rahimi-Kakhki R, Zargaran B, Ferns GA, Avan A. Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis. Curr Drug Targets 2019;20:1447-60. [PMID: 31284859 DOI: 10.2174/1389450120666190708100308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Mahdian-Shakib A, Dorostkar R, Tat M, Hashemzadeh MS, Saidi N. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer. Biomed Pharmacother 2016;84:592-600. [PMID: 27694003 DOI: 10.1016/j.biopha.2016.09.087] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
8 Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA, Sarkar FH. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010;70:3606-3617. [PMID: 20388782 DOI: 10.1158/0008-5472.can-09-4598] [Cited by in Crossref: 315] [Cited by in F6Publishing: 169] [Article Influence: 26.3] [Reference Citation Analysis]
9 Koutsaki M, Libra M, Spandidos DA, Zaravinos A. The miR-200 family in ovarian cancer. Oncotarget 2017;8:66629-40. [PMID: 29029543 DOI: 10.18632/oncotarget.18343] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
10 Wang Y, Xu X, Yu S, Jeong KJ, Zhou Z, Han L, Tsang YH, Li J, Chen H, Mangala LS, Yuan Y, Eterovic AK, Lu Y, Sood AK, Scott KL, Mills GB, Liang H. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res 2017;27:1112-25. [PMID: 28411194 DOI: 10.1101/gr.219741.116] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 18.6] [Reference Citation Analysis]
11 Prahm KP, Novotny GW, Høgdall C, Høgdall E. Current status on microRNAs as biomarkers for ovarian cancer. APMIS 2016;124:337-55. [PMID: 26809719 DOI: 10.1111/apm.12514] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
12 Wiemer EA, Berns EM. microRNAs in stage I epithelial ovarian cancer. Lancet Oncol 2011;12:208-9. [PMID: 21345724 DOI: 10.1016/S1470-2045(11)70038-9] [Reference Citation Analysis]
13 Babashah S. MicroRNAs and Cancer: An Overview. In: Babashah S, editor. MicroRNAs: Key Regulators of Oncogenesis. Cham: Springer International Publishing; 2014. pp. 3-28. [DOI: 10.1007/978-3-319-03725-7_1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
14 Davidson B, Tropé CG, Reich R. The clinical and diagnostic role of microRNAs in ovarian carcinoma. Gynecologic Oncology 2014;133:640-6. [DOI: 10.1016/j.ygyno.2014.03.575] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
15 Shen LJ, He JL, Yang DH, Ding YB, Chen XM, Geng YQ, Liu SJ, Liu XQ, Wang YX. Mmu-microRNA-200a overexpression leads to implantation defect by targeting phosphatase and tensin homolog in mouse uterus. Reprod Sci 2013;20:1518-28. [PMID: 23690337 DOI: 10.1177/1933719113488453] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
16 Snowdon J, Zhang X, Childs T, Tron VA, Feilotter H. The microRNA-200 family is upregulated in endometrial carcinoma. PLoS One 2011;6:e22828. [PMID: 21897839 DOI: 10.1371/journal.pone.0022828] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 7.9] [Reference Citation Analysis]
17 Hui A, How C, Ito E, Liu FF. Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer. 2011;11:500. [PMID: 22128797 DOI: 10.1186/147-2407-11-500] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Li MH, Fu SB, Xiao HS. Genome-wide analysis of microRNA and mRNA expression signatures in cancer. Acta Pharmacol Sin 2015;36:1200-11. [PMID: 26299954 DOI: 10.1038/aps.2015.67] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
19 Zhao L, Chen X, Cao Y. New role of microRNA: carcinogenesis and clinical application in cancer. Acta Biochim Biophys Sin (Shanghai). 2011;43:831-839. [PMID: 21908856 DOI: 10.1093/abbs/gmr080] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
20 Li C, Feng Y, Coukos G, Zhang L. MicroRNAs in Epithelial Ovarian Cancer. In: Cho WC, editor. MicroRNAs in Cancer Translational Research. Dordrecht: Springer Netherlands; 2011. pp. 309-42. [DOI: 10.1007/978-94-007-0298-1_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Langhe R. microRNA and Ovarian Cancer. In: Santulli G, editor. microRNA: Cancer. Cham: Springer International Publishing; 2015. pp. 119-51. [DOI: 10.1007/978-3-319-23730-5_8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
22 Hillman Y, Mazkereth N, Farberov L, Shomron N, Fishelson Z. Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217. J Immunol 2016;196:5156-65. [PMID: 27183614 DOI: 10.4049/jimmunol.1502701] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
23 Foster R, Buckanovich RJ, Rueda BR. Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett 2013;338:147-57. [PMID: 23138176 DOI: 10.1016/j.canlet.2012.10.023] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 7.6] [Reference Citation Analysis]
24 Agostini A, Brunetti M, Davidson B, Tropé CG, Eriksson AGZ, Heim S, Panagopoulos I, Micci F. The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas. Sci Rep 2018;8:11069. [PMID: 30038317 DOI: 10.1038/s41598-018-29332-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
25 Nana-Sinkam SP, Croce CM. MicroRNAs as therapeutic targets in cancer. Transl Res 2011;157:216-25. [PMID: 21420032 DOI: 10.1016/j.trsl.2011.01.013] [Cited by in Crossref: 107] [Cited by in F6Publishing: 109] [Article Influence: 9.7] [Reference Citation Analysis]
26 Tsouko E, Wang J, Frigo DE, Aydoğdu E, Williams C. miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. Carcinogenesis 2015;36:1051-60. [PMID: 26088362 DOI: 10.1093/carcin/bgv087] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 6.7] [Reference Citation Analysis]
27 Liu L, Chen Q, Lai R, Wu X, Wu X, Liu F, Xu G, Ji Y. Elevated expression of mature miR-21 and miR-155 in cancerous gastric tissues from Chinese patients with gastric cancer. J Biomed Res. 2010;24:187-197. [PMID: 23554630 DOI: 10.1016/s1674-8301(10)60028-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
28 Delfino KR, Rodriguez-Zas SL. Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence. PLoS One 2013;8:e58608. [PMID: 23554906 DOI: 10.1371/journal.pone.0058608] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
29 Balch C, Matei DE, Huang TH, Nephew KP. Role of epigenomics in ovarian and endometrial cancers. Epigenomics 2010;2:419-47. [PMID: 22121902 DOI: 10.2217/epi.10.19] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
30 Ungewiss C, Rizvi ZH, Roybal JD, Peng DH, Gold KA, Shin DH, Creighton CJ, Gibbons DL. The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. Sci Rep 2016;6:18652. [PMID: 26728244 DOI: 10.1038/srep18652] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 7.5] [Reference Citation Analysis]
31 Muralidhar GG, Barbolina MV. The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer. Int J Mol Sci 2015;16:16833-47. [PMID: 26213923 DOI: 10.3390/ijms160816833] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
32 Manavalan TT, Teng Y, Litchfield LM, Muluhngwi P, Al-Rayyan N, Klinge CM. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS One 2013;8:e62334. [PMID: 23626803 DOI: 10.1371/journal.pone.0062334] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 7.9] [Reference Citation Analysis]
33 Li SD, Zhang JR, Wang YQ, Wan XP. The role of microRNAs in ovarian cancer initiation and progression. J Cell Mol Med 2010;14:2240-9. [PMID: 20345848 DOI: 10.1111/j.1582-4934.2010.01058.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
34 Ferneza S, Fetsych M, Shuliak R, Makukh H, Volodko N, Yarema R, Fetsych T. Clinical significance of microRNA-200 and let-7 families expression assessment in patients with ovarian cancer. Ecancermedicalscience 2021;15:1249. [PMID: 34267805 DOI: 10.3332/ecancer.2021.1249] [Reference Citation Analysis]
35 Braicu OL, Budisan L, Buiga R, Jurj A, Achimas-Cadariu P, Pop LA, Braicu C, Irimie A, Berindan-Neagoe I. miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples. Onco Targets Ther 2017;10:4225-38. [PMID: 28894379 DOI: 10.2147/OTT.S137107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
36 Brücher BL, Li Y, Schnabel P, Daumer M, Wallace TJ, Kube R, Zilberstein B, Steele S, Voskuil JL, Jamall IS. Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers. Clin Transl Med 2016;5:13. [PMID: 27053248 DOI: 10.1186/s40169-016-0093-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
37 Yerukala Sathipati S, Ho SY. Identifying a miRNA signature for predicting the stage of breast cancer. Sci Rep 2018;8:16138. [PMID: 30382159 DOI: 10.1038/s41598-018-34604-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
38 Zhang Z, Lanz RB, Xiao L, Wang L, Hartig SM, Ittmann MM, Feng Q, He B. The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors. Oncotarget 2016;7:37993-8003. [PMID: 27191272 DOI: 10.18632/oncotarget.9366] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
39 Li L, Tang J, Zhang B, Yang W, LiuGao M, Wang R, Tan Y, Fan J, Chang Y, Fu J, Jiang F, Chen C, Yang Y, Gu J, Wu D, Guo L, Cao D, Li H, Cao G, Wu M, Zhang MQ, Chen L, Wang H. Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4. Gut. 2015;64:156-167. [PMID: 24572141 DOI: 10.1136/gutjnl-2013-305715] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 10.3] [Reference Citation Analysis]
40 Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. J Cell Physiol. 2019;234:12369-12384. [PMID: 30605237 DOI: 10.1002/jcp.28058] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 21.0] [Reference Citation Analysis]
41 Vallejo DM, Caparros E, Dominguez M. Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. EMBO J 2011;30:756-69. [PMID: 21224847 DOI: 10.1038/emboj.2010.358] [Cited by in Crossref: 116] [Cited by in F6Publishing: 109] [Article Influence: 10.5] [Reference Citation Analysis]
42 Huang G, Sun J, Lu Y, Liu Y, Cao H, Zhang H, Calin GA. MiR-200 family and cancer: From a meta-analysis view. Molecular Aspects of Medicine 2019;70:57-71. [DOI: 10.1016/j.mam.2019.09.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
43 Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H. Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer. Adv Exp Med Biol 2016;924:3-8. [PMID: 27753009 DOI: 10.1007/978-3-319-42044-8_1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
44 Feng X, Wang Z, Fillmore R, Xi Y. MiR-200, a new star miRNA in human cancer. Cancer Lett. 2014;344:166-173. [PMID: 24262661 DOI: 10.1016/j.canlet.2013.11.004] [Cited by in Crossref: 216] [Cited by in F6Publishing: 220] [Article Influence: 24.0] [Reference Citation Analysis]
45 Kabekkodu SP, Shukla V, Varghese VK, Adiga D, Vethil Jishnu P, Chakrabarty S, Satyamoorthy K. Cluster miRNAs and cancer: Diagnostic, prognostic and therapeutic opportunities. Wiley Interdiscip Rev RNA 2020;11:e1563. [PMID: 31436881 DOI: 10.1002/wrna.1563] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
46 Shuang T, Wang M, Chang S. Hybrid-polymerase chain reaction to identify novel target genes of miR-134 in paclitaxel resistant human ovarian carcinoma cells. Oncol Lett 2015;9:2910-6. [PMID: 26137169 DOI: 10.3892/ol.2015.3137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
47 Li M, Li J, Ding X, He M, Cheng SY. microRNA and cancer. AAPS J 2010;12:309-17. [PMID: 20422339 DOI: 10.1208/s12248-010-9194-0] [Cited by in Crossref: 99] [Cited by in F6Publishing: 95] [Article Influence: 8.3] [Reference Citation Analysis]
48 Lu Y, Shang C, Ou Y, Yin D, Li Y, Li X, Wang N, Zhang S. miR-200c modulates ovarian cancer cell metastasis potential by targeting zinc finger E-box-binding homeobox 2 (ZEB2) expression. Med Oncol 2014;31. [DOI: 10.1007/s12032-014-0134-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
49 Tejero R, Navarro A, Campayo M, Viñolas N, Marrades RM, Cordeiro A, Ruíz-Martínez M, Santasusagna S, Molins L, Ramirez J, Monzó M. miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. PLoS One 2014;9:e101899. [PMID: 25003366 DOI: 10.1371/journal.pone.0101899] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 9.9] [Reference Citation Analysis]
50 Katz B, Reis ST, Viana NI, Morais DR, Moura CM, Dip N, Silva IA, Iscaife A, Srougi M, Leite KR. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer. PLoS One 2014;9:e113700. [PMID: 25409297 DOI: 10.1371/journal.pone.0113700] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
51 Engelsvold DH, Utheim TP, Olstad OK, Gonzalez P, Eidet JR, Lyberg T, Trøseid AM, Dartt DA, Raeder S. miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. Exp Eye Res 2013;115:189-98. [PMID: 23872359 DOI: 10.1016/j.exer.2013.07.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
52 Liu D, Xia P, Diao D, Cheng Y, Zhang H, Yuan D, Huang C, Dang C. MiRNA-429 suppresses the growth of gastric cancer cells in vitro. J Biomed Res 2012;26:389-93. [PMID: 23554776 DOI: 10.7555/JBR.26.20120029] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
53 Ribeiro-dos-Santos Â, Khayat AS, Silva A, Alencar DO, Lobato J, Luz L, Pinheiro DG, Varuzza L, Assumpção M, Assumpção P, Santos S, Zanette DL, Silva WA Jr, Burbano R, Darnet S. Ultra-deep sequencing reveals the microRNA expression pattern of the human stomach. PLoS One 2010;5:e13205. [PMID: 20949028 DOI: 10.1371/journal.pone.0013205] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
54 Dai X, Tan C. Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers. Adv Drug Deliv Rev 2015;81:184-97. [PMID: 25281917 DOI: 10.1016/j.addr.2014.09.010] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 11.1] [Reference Citation Analysis]
55 Giampaolino P, Foreste V, Della Corte L, Di Filippo C, Iorio G, Bifulco G. Role of biomarkers for early detection of ovarian cancer recurrence. Gland Surg 2020;9:1102-11. [PMID: 32953625 DOI: 10.21037/gs-20-544] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
56 Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, Suciu N, Cretoiu SM, Voinea SC. miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells 2020;9:E276. [PMID: 31979244 DOI: 10.3390/cells9020276] [Cited by in Crossref: 132] [Cited by in F6Publishing: 131] [Article Influence: 66.0] [Reference Citation Analysis]
57 Wright JA, Richer JK, Goodall GJ. microRNAs and EMT in Mammary Cells and Breast Cancer. J Mammary Gland Biol Neoplasia 2010;15:213-23. [DOI: 10.1007/s10911-010-9183-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
58 Meng X, Joosse SA, Müller V, Trillsch F, Milde-Langosch K, Mahner S, Geffken M, Pantel K, Schwarzenbach H. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. Br J Cancer 2015;113:1358-66. [PMID: 26393886 DOI: 10.1038/bjc.2015.340] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 10.6] [Reference Citation Analysis]
59 Xia H, Cheung WK, Sze J, Lu G, Jiang S, Yao H, Bian XW, Poon WS, Kung HF, Lin MC. miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling. J Biol Chem. 2010;285:36995-37004. [PMID: 20826811 DOI: 10.1074/jbc.m110.133744] [Cited by in Crossref: 82] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
60 Hünten S, Siemens H, Kaller M, Hermeking H. The p53/microRNA Network in Cancer: Experimental and Bioinformatics Approaches. In: Schmitz U, Wolkenhauer O, Vera J, editors. MicroRNA Cancer Regulation. Dordrecht: Springer Netherlands; 2013. pp. 77-101. [DOI: 10.1007/978-94-007-5590-1_5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
61 De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97-110. [PMID: 23344542 DOI: 10.1038/nrc3447] [Cited by in Crossref: 1460] [Cited by in F6Publishing: 1424] [Article Influence: 162.2] [Reference Citation Analysis]
62 Ahmed N, Abubaker K, Findlay J, Quinn M. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem. 2013;114:21-34. [PMID: 22887554 DOI: 10.1002/jcb.24317] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 7.3] [Reference Citation Analysis]
63 Lin K, Xu T, He BS, Pan YQ, Sun HL, Peng HX, Hu XX, Wang SK. MicroRNA expression profiles predict progression and clinical outcome in lung adenocarcinoma. Onco Targets Ther 2016;9:5679-92. [PMID: 27695346 DOI: 10.2147/OTT.S111241] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
64 Jiang K, Zhang M, Li F, Li D, Sun G, Liu X, Li H, Han R, Jiang R, Li Z, Kang X, Yan F. Study on the role of gga-miRNA-200a in regulating cell differentiation and proliferation of chicken breast muscle by targeting Grb2. Animal Cells and Systems 2017;21:365-73. [DOI: 10.1080/19768354.2017.1400465] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
65 Sánchez-Aragó M, Formentini L, Martínez-Reyes I, García-Bermudez J, Santacatterina F, Sánchez-Cenizo L, Willers IM, Aldea M, Nájera L, Juarránz A, López EC, Clofent J, Navarro C, Espinosa E, Cuezva JM. Expression, regulation and clinical relevance of the ATPase inhibitory factor 1 in human cancers. Oncogenesis 2013;2:e46. [PMID: 23608753 DOI: 10.1038/oncsis.2013.9] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 5.4] [Reference Citation Analysis]
66 Kinose Y, Sawada K, Nakamura K, Kimura T. The role of microRNAs in ovarian cancer. Biomed Res Int. 2014;2014:249393. [PMID: 25295252 DOI: 10.1155/2014/249393] [Cited by in Crossref: 82] [Cited by in F6Publishing: 90] [Article Influence: 10.3] [Reference Citation Analysis]
67 Senol O, Schaaij-Visser TB, Erkan EP, Dorfer C, Lewandrowski G, Pham TV, Piersma SR, Peerdeman SM, Ströbel T, Tannous B, Saydam N, Slavc I, Knosp E, Jimenez CR, Saydam O. miR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth in vivo. Oncogene 2015;34:1790-8. [PMID: 24858044 DOI: 10.1038/onc.2014.120] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
68 Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, Nicolas A, Meyniel J, Cottu P, Sastre-garau X, Mechta-grigoriou F. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 2011;17:1627-35. [DOI: 10.1038/nm.2512] [Cited by in Crossref: 312] [Cited by in F6Publishing: 290] [Article Influence: 28.4] [Reference Citation Analysis]
69 Deb B, Uddin A, Chakraborty S. miRNAs and ovarian cancer: An overview. J Cell Physiol 2018;233:3846-54. [PMID: 28703277 DOI: 10.1002/jcp.26095] [Cited by in Crossref: 62] [Cited by in F6Publishing: 71] [Article Influence: 12.4] [Reference Citation Analysis]
70 Prahm KP, Høgdall C, Karlsen MA, Christensen IJ, Novotny GW, Høgdall E. Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. PLoS One 2018;13:e0207319. [PMID: 30475821 DOI: 10.1371/journal.pone.0207319] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
71 Antony J, Thiery JP, Huang RY. Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention. Phys Biol 2019;16:041004. [DOI: 10.1088/1478-3975/ab157a] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
72 Sinha M, Ghatak S, Roy S, Sen CK. microRNA-200b as a Switch for Inducible Adult Angiogenesis. Antioxid Redox Signal 2015;22:1257-72. [PMID: 25761972 DOI: 10.1089/ars.2014.6065] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
73 Bibi F, Naseer MI, Alvi SA, Yasir M, Jiman-Fatani AA, Sawan A, Abuzenadah AM, Al-Qahtani MH, Azhar EI. microRNA analysis of gastric cancer patients from Saudi Arabian population. BMC Genomics. 2016;17:751. [PMID: 27766962 DOI: 10.1186/s12864-016-3090-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
74 Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther 2012;11:2556-65. [PMID: 23074172 DOI: 10.1158/1535-7163.MCT-12-0463] [Cited by in Crossref: 89] [Cited by in F6Publishing: 54] [Article Influence: 8.9] [Reference Citation Analysis]
75 Wahab NA, Othman Z, Nasri NWM, Mokhtar MH, Ibrahim SF, Hamid AA, Raja Ali RA, Mokhtar NM. Inhibition of miR-141 and miR-200a Increase DLC-1 and ZEB2 Expression, Enhance Migration and Invasion in Metastatic Serous Ovarian Cancer. Int J Environ Res Public Health 2020;17:E2766. [PMID: 32316405 DOI: 10.3390/ijerph17082766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
76 Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei Y, Li Y, Yang Q, Liu J, Wei JJ, Shao C, Liu Z, Kong B. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget 2014;5:10816-29. [PMID: 25333261 DOI: 10.18632/oncotarget.2522] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 9.6] [Reference Citation Analysis]
77 Lu Y, Lu J, Li X, Zhu H, Fan X, Zhu S, Wang Y, Guo Q, Wang L, Huang Y. MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell. BMC Cancer. 2014;14:85. [PMID: 24521357 DOI: 10.1186/1471-2407-14-85] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 6.8] [Reference Citation Analysis]
78 Ye C, Sun N, Ma Y, Zhao Q, Zhang Q, Xu C, Wang S, Sun S, Wang F, Li W. MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells. FEBS Letters 2015;589:702-9. [DOI: 10.1016/j.febslet.2015.01.037] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
79 Dwivedi SKD, Rao G, Dey A, Mukherjee P, Wren JD, Bhattacharya R. Small Non-Coding-RNA in Gynecological Malignancies. Cancers (Basel) 2021;13:1085. [PMID: 33802524 DOI: 10.3390/cancers13051085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
80 Sun N, Zhang Q, Xu C, Zhao Q, Ma Y, Lu X, Wang L, Li W. Molecular regulation of ovarian cancer cell invasion. Tumor Biol 2014;35:11359-66. [DOI: 10.1007/s13277-014-2434-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
81 Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H, LLeonart ME. Oxidative stress and cancer: an overview. Ageing Res Rev 2013;12:376-90. [PMID: 23123177 DOI: 10.1016/j.arr.2012.10.004] [Cited by in Crossref: 648] [Cited by in F6Publishing: 600] [Article Influence: 64.8] [Reference Citation Analysis]
82 Sulaiman SA, Ab Mutalib NS, Jamal R. miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition. Front Pharmacol 2016;7:271. [PMID: 27601996 DOI: 10.3389/fphar.2016.00271] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
83 Lu R, Ji Z, Li X, Qin J, Cui G, Chen J, Zhai Q, Zhao C, Zhang W, Yu Z. Tumor suppressive microRNA-200a inhibits renal cell carcinoma development by directly targeting TGFB2. Tumour Biol 2015;36:6691-700. [PMID: 25813153 DOI: 10.1007/s13277-015-3355-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
84 Safari A, Seifoleslami M, Yahaghi E, Sedaghati F, Khameneie MK. RETRACTED ARTICLE: Upregulation of miR-20a and miR-10a expression levels act as potential biomarkers of aggressive progression and poor prognosis in cervical cancer. Tumour Biol 2015. [PMID: 26427662 DOI: 10.1007/s13277-015-4064-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
85 Pereira-terra P, Deprest JA, Kholdebarin R, Khoshgoo N, Dekoninck P, Munck AAB, Wang J, Zhu F, Rottier RJ, Iwasiow BM, Correia-pinto J, Tibboel D, Post M, Keijzer R. Unique Tracheal Fluid MicroRNA Signature Predicts Response to FETO in Patients With Congenital Diaphragmatic Hernia. Annals of Surgery 2015;262:1130-40. [DOI: 10.1097/sla.0000000000001054] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
86 Di Leva G, Croce CM. The Role of microRNAs in the Tumorigenesis of Ovarian Cancer. Front Oncol 2013;3:153. [PMID: 23785667 DOI: 10.3389/fonc.2013.00153] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 6.7] [Reference Citation Analysis]
87 Vaz C, Ahmad HM, Sharma P, Gupta R, Kumar L, Kulshreshtha R, Bhattacharya A. Analysis of microRNA transcriptome by deep sequencing of small RNA libraries of peripheral blood. BMC Genomics 2010;11:288. [PMID: 20459673 DOI: 10.1186/1471-2164-11-288] [Cited by in Crossref: 116] [Cited by in F6Publishing: 108] [Article Influence: 9.7] [Reference Citation Analysis]
88 Chen SN, Chang R, Lin LT, Chern CU, Tsai HW, Wen ZH, Li YH, Li CJ, Tsui KH. MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities. Int J Environ Res Public Health 2019;16:E1510. [PMID: 31035447 DOI: 10.3390/ijerph16091510] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
89 Nagaraj AB, Joseph P, DiFeo A. miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer. Biomark Med. 2015;9:241-257. [PMID: 25731210 DOI: 10.2217/bmm.14.108] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
90 Shi M, Mu Y, Zhang H, Liu M, Wan J, Qin X, Li C. MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis. Medicine (Baltimore) 2018;97:e11505. [PMID: 30095616 DOI: 10.1097/MD.0000000000011505] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
91 Yin Y, Song WW, Wang Y, Zhao W, Wu J, Xu W. MicroRNA-200 families and prognostic value in various carcinomas: A systematic review and meta-analysis. Aging Med (Milton) 2018;1:39-45. [PMID: 31942478 DOI: 10.1002/agm2.12005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Sun T, Wang C, Xing J, Wu D. miR-429 modulates the expression of c-myc in human gastric carcinoma cells. Eur J Cancer 2011;47:2552-9. [PMID: 21684154 DOI: 10.1016/j.ejca.2011.05.021] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 5.6] [Reference Citation Analysis]
93 Shi C, Zhang Z. The prognostic value of the miR-200 family in ovarian cancer: a meta-analysis. Acta Obstet Gynecol Scand 2016;95:505-12. [DOI: 10.1111/aogs.12883] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
94 Javadi M, Rad JS, Farashah MSG, Roshangar L. An Insight on the Role of Altered Function and Expression of Exosomes and MicroRNAs in Female Reproductive Diseases. Reprod Sci 2021. [PMID: 33825167 DOI: 10.1007/s43032-021-00556-9] [Reference Citation Analysis]
95 Jin T, Suk Kim H, Ki Choi S, Hye Hwang E, Woo J, Suk Ryu H, Kim K, Moon A, Kyung Moon W. microRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival. Oncotarget 2017;8:32769-82. [PMID: 28427146 DOI: 10.18632/oncotarget.15680] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
96 Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget 2016;7:16923-35. [PMID: 26943577 DOI: 10.18632/oncotarget.7850] [Cited by in Crossref: 121] [Cited by in F6Publishing: 131] [Article Influence: 24.2] [Reference Citation Analysis]
97 Wang M, Zhang P, Li Y, Liu G, Zhou B, Zhan L, Zhou Z, Sun X. The quantitative analysis by stem-loop real-time PCR revealed the microRNA-34a, microRNA-155 and microRNA-200c overexpression in human colorectal cancer. Med Oncol. 2012;29:3113-3118. [PMID: 22562822 DOI: 10.1007/s12032-012-0241-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
98 Au KK, Josahkian JA, Francis J, Squire JA, Koti M. Current state of biomarkers in ovarian cancer prognosis. Future Oncology 2015;11:3187-95. [DOI: 10.2217/fon.15.251] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
99 Lam SS, Mak AS, Yam JW, Cheung AN, Ngan HY, Wong AS. Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells. Mol Ther. 2014;22:743-751. [PMID: 24419103 DOI: 10.1038/mt.2014.1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
100 Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, Swisher SG, Wu TT, Ajani JA, Xu XC. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 2011;128:132-143. [PMID: 20309880 DOI: 10.1002/ijc.25330] [Cited by in Crossref: 113] [Cited by in F6Publishing: 115] [Article Influence: 9.4] [Reference Citation Analysis]
101 Chen X, Li Y, Zuo C, Zhang K, Lei X, Wang J, Yang Y, Zhang J, Ma K, Wang S, Mu N, Yang C, Xian J, Feng H, Tang R, Chen T. Long Non-Coding RNA H19 Regulates Glioma Cell Growth and Metastasis via miR-200a-Mediated CDK6 and ZEB1 Expression. Front Oncol 2021;11:757650. [PMID: 34796112 DOI: 10.3389/fonc.2021.757650] [Reference Citation Analysis]
102 Wu Q, Guo R, Lin M, Zhou B, Wang Y. MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecol Oncol 2011;122:149-54. [PMID: 21529905 DOI: 10.1016/j.ygyno.2011.03.026] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
103 Sayed D, Abdellatif M. MicroRNAs in Development and Disease. Physiological Reviews 2011;91:827-87. [DOI: 10.1152/physrev.00006.2010] [Cited by in Crossref: 691] [Cited by in F6Publishing: 675] [Article Influence: 62.8] [Reference Citation Analysis]
104 Sarojini S, Tamir A, Lim H, Li S, Zhang S, Goy A, Pecora A, Suh KS. Early detection biomarkers for ovarian cancer. J Oncol 2012;2012:709049. [PMID: 23319948 DOI: 10.1155/2012/709049] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
105 Davidson B, Tropé CG. Ovarian cancer: diagnostic, biological and prognostic aspects. Womens Health (Lond) 2014;10:519-33. [PMID: 25335543 DOI: 10.2217/whe.14.37] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
106 Wu L, Shang W, Zhao H, Rong G, Zhang Y, Xu T, Zhang J, Huang P, Wang F. In Silico Screening of Circulating MicroRNAs as Potential Biomarkers for the Diagnosis of Ovarian Cancer. Dis Markers 2019;2019:7541857. [PMID: 31467618 DOI: 10.1155/2019/7541857] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
107 Zhang B, Xing X, Li J, Lowdon RF, Zhou Y, Lin N, Zhang B, Sundaram V, Chiappinelli KB, Hagemann IS, Mutch DG, Goodfellow PJ, Wang T. Comparative DNA methylome analysis of endometrial carcinoma reveals complex and distinct deregulation of cancer promoters and enhancers. BMC Genomics 2014;15:868. [PMID: 25286960 DOI: 10.1186/1471-2164-15-868] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
108 Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol 2010;42:1262-72. [PMID: 20035894 DOI: 10.1016/j.biocel.2009.12.017] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
109 Singh A, Gupta S, Sachan M. Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives. Front Cell Dev Biol 2019;7:182. [PMID: 31608277 DOI: 10.3389/fcell.2019.00182] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
110 Zaman MS, Maher DM, Khan S, Jaggi M, Chauhan SC. Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res 2012;5:44. [PMID: 23237306 DOI: 10.1186/1757-2215-5-44] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
111 Humphries B, Yang C. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget 2015;6:6472-98. [PMID: 25762624 DOI: 10.18632/oncotarget.3052] [Cited by in Crossref: 183] [Cited by in F6Publishing: 195] [Article Influence: 30.5] [Reference Citation Analysis]
112 Fan C, Hu R, Fan H, Yang Y, Gong B, Zhang S, Ding J, Su Y, Zhuo Z, Cheng J. Effects of seasonal ambient heat stress on expression of microRNAs in the mammary gland of Holstein cows. Int J Biometeorol 2021;65:235-46. [PMID: 33118114 DOI: 10.1007/s00484-020-02025-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Lee AH, Ghosh D, Quach N, Schroeder D, Dawson MR. Ovarian Cancer Exosomes Trigger Differential Biophysical Response in Tumor-Derived Fibroblasts. Sci Rep 2020;10:8686. [PMID: 32457479 DOI: 10.1038/s41598-020-65628-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
114 Muinao T, Deka Boruah HP, Pal M. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells – An updated review. Experimental Cell Research 2018;362:1-10. [DOI: 10.1016/j.yexcr.2017.10.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 12.3] [Reference Citation Analysis]
115 Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, Wang Z. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 2010;119:125-130. [PMID: 20624637 DOI: 10.1016/j.ygyno.2010.06.004] [Cited by in Crossref: 130] [Cited by in F6Publishing: 118] [Article Influence: 10.8] [Reference Citation Analysis]
116 Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer 2014;14:80. [PMID: 24512620 DOI: 10.1186/1471-2407-14-80] [Cited by in Crossref: 63] [Cited by in F6Publishing: 71] [Article Influence: 7.9] [Reference Citation Analysis]
117 Gallagher MF, Flavin RJ, Elbaruni SA, McInerney JK, Smyth PC, Salley YM, Vencken SF, O'Toole SA, Laios A, Lee MY, Denning K, Li J, Aherne ST, Lao KQ, Martin CM, Sheils OM, O'Leary JJ. Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients. J Ovarian Res 2009;2:19. [PMID: 20015364 DOI: 10.1186/1757-2215-2-19] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
118 Sun T, Kong X, Du Y, Li Z. Aberrant MicroRNAs in Pancreatic Cancer: Researches and Clinical Implications. Gastroenterol Res Pract 2014;2014:386561. [PMID: 24899890 DOI: 10.1155/2014/386561] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
119 Fang Y, Xu C, Fu Y. MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling. J Biol Res (Thessalon) 2015;22:12. [PMID: 26500892 DOI: 10.1186/s40709-015-0035-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
120 Prislei S, Martinelli E, Mariani M, Raspaglio G, Sieber S, Ferrandina G, Shahabi S, Scambia G, Ferlini C. MiR-200c and HuR in ovarian cancer. BMC Cancer 2013;13:72. [PMID: 23394580 DOI: 10.1186/1471-2407-13-72] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
121 El Naqa I. Biomedical informatics and panomics for evidence-based radiation therapy. WIREs Data Mining Knowl Discov 2014;4:327-40. [DOI: 10.1002/widm.1131] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
122 Kafshdooz L, Pourfathi H, Akbarzadeh A, Kafshdooz T, Razban Z, Sheervalilou R, Ebrahimi Sadr N, Khalilov R, Saghfi S, Kavetskyy T, Mammadova L, Mehrizadeh M, Ghasemali S. The role of microRNAs and nanoparticles in ovarian cancer: a review. Artificial Cells, Nanomedicine, and Biotechnology 2018;46:241-7. [DOI: 10.1080/21691401.2018.1454931] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
123 Sandhu S, Garzon R. Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. Semin Oncol 2011;38:781-7. [PMID: 22082764 DOI: 10.1053/j.seminoncol.2011.08.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
124 Lin CC, Chen YJ, Chen CY, Oyang YJ, Juan HF, Huang HC. Crosstalk between transcription factors and microRNAs in human protein interaction network. BMC Syst Biol 2012;6:18. [PMID: 22413876 DOI: 10.1186/1752-0509-6-18] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
125 Luo P, Liu XF, Wang YC, Li ND, Liao SJ, Yu MX, Liang CZ, Tu JC. Prognostic value of abnormally expressed lncRNAs in ovarian carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:23927-36. [PMID: 28118613 DOI: 10.18632/oncotarget.14760] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
126 Labib M, Khan N, Ghobadloo SM, Cheng J, Pezacki JP, Berezovski MV. Three-mode electrochemical sensing of ultralow microRNA levels. J Am Chem Soc 2013;135:3027-38. [PMID: 23362834 DOI: 10.1021/ja308216z] [Cited by in Crossref: 164] [Cited by in F6Publishing: 146] [Article Influence: 18.2] [Reference Citation Analysis]
127 Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, Jiang B, Shu Y, Liu P. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012;69:723-31. [PMID: 21993663 DOI: 10.1007/s00280-011-1752-3] [Cited by in Crossref: 130] [Cited by in F6Publishing: 130] [Article Influence: 11.8] [Reference Citation Analysis]
128 Mardis ER, Wilson RK. Cancer genome sequencing: a review. Hum Mol Genet 2009;18:R163-8. [PMID: 19808792 DOI: 10.1093/hmg/ddp396] [Cited by in Crossref: 138] [Cited by in F6Publishing: 113] [Article Influence: 10.6] [Reference Citation Analysis]
129 Chen J, Wang L, Matyunina LV, Hill CG, McDonald JF. Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol. 2011;121:200-205. [PMID: 21277012 DOI: 10.1016/j.ygyno.2010.12.339] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 8.5] [Reference Citation Analysis]
130 Ferreira P, Roela RA, Lopez RVM, Del Pilar Estevez-Diz M. The prognostic role of microRNA in epithelial ovarian cancer: a systematic review of literature with an overall survival meta-analysis. Oncotarget 2020;11:1085-95. [PMID: 32256980 DOI: 10.18632/oncotarget.27246] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
131 Li LW, Xiao HQ, Ma R, Yang M, Li W, Lou G. miR-152 is involved in the proliferation and metastasis of ovarian cancer through repression of ERBB3. Int J Mol Med 2018;41:1529-35. [PMID: 29286064 DOI: 10.3892/ijmm.2017.3324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
132 Bovell LC, Putcha BD, Samuel T, Manne U. Clinical implications of microRNAs in cancer. Biotech Histochem 2013;88:388-96. [PMID: 23647010 DOI: 10.3109/10520295.2013.788735] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
133 Mirahmadi Y, Nabavi R, Taheri F, Samadian MM, Ghale-Noie ZN, Farjami M, Samadi-Khouzani A, Yousefi M, Azhdari S, Salmaninejad A, Sahebkar A. MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer. J Oncol 2021;2021:3408937. [PMID: 34721577 DOI: 10.1155/2021/3408937] [Reference Citation Analysis]
134 Ma Y, Lu Y, Lu B. MicroRNA and Long Non-Coding RNA in Ovarian Carcinoma: Translational Insights and Potential Clinical Applications. Cancer Invest 2016;34:465-76. [PMID: 27673409 DOI: 10.1080/07357907.2016.1227446] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
135 Duran GE, Wang YC, Moisan F, Francisco EB, Sikic BI. Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition. Br J Cancer 2017;116:1318-28. [PMID: 28399108 DOI: 10.1038/bjc.2017.102] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
136 Torres A, Torres K, Maciejewski R, Harvey WH. MicroRNAs and their role in gynecological tumors. Med Res Rev 2011;31:895-923. [PMID: 20358579 DOI: 10.1002/med.20205] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
137 Staicu CE, Predescu DV, Rusu CM, Radu BM, Cretoiu D, Suciu N, Crețoiu SM, Voinea SC. Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview. Cells 2020;9:E169. [PMID: 31936634 DOI: 10.3390/cells9010169] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
138 Shih KK, Qin LX, Tanner EJ, Zhou Q, Bisogna M, Dao F, Olvera N, Viale A, Barakat RR, Levine DA. A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol Oncol 2011;121:444-50. [PMID: 21354599 DOI: 10.1016/j.ygyno.2011.01.025] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
139 Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol. 2013;774:1-20. [PMID: 23377965 DOI: 10.1007/978-94-007-5590-1_1] [Cited by in Crossref: 426] [Cited by in F6Publishing: 432] [Article Influence: 47.3] [Reference Citation Analysis]
140 Gadducci A, Sergiampietri C, Lanfredini N, Guiggi I. Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research. Gynecol Endocrinol 2014;30:266-71. [PMID: 24479883 DOI: 10.3109/09513590.2013.871525] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
141 Wang J, Wang C, Li Q, Guo C, Sun W, Zhao D, Jiang S, Hao L, Tian Y, Liu S, Sun MZ. miR-429-CRKL axis regulates clear cell renal cell carcinoma malignant progression through SOS1/MEK/ERK/MMP2/MMP9 pathway. Biomed Pharmacother 2020;127:110215. [PMID: 32413671 DOI: 10.1016/j.biopha.2020.110215] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
142 Lee H, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE, Swisher E, Kiviat NB, Feng Q. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol. 2012;10:174. [PMID: 22925189 DOI: 10.1186/1477-7819-10-174] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 7.2] [Reference Citation Analysis]
143 Guo C, Gao C, Zhao D, Li J, Wang J, Sun X, Liu Q, Hao L, Greenaway FT, Tian Y, Liu S, Sun MZ. A novel ETV6-miR-429-CRKL regulatory circuitry contributes to aggressiveness of hepatocellular carcinoma. J Exp Clin Cancer Res 2020;39:70. [PMID: 32326970 DOI: 10.1186/s13046-020-01559-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
144 So KA, Hong JH, Jin HM, Kim JW, Song JY, Lee JK, Lee NW. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study. Gynecol Oncol 2014;132:551-5. [PMID: 24440470 DOI: 10.1016/j.ygyno.2014.01.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
145 Pal MK, Jaiswar SP, Dwivedi VN, Tripathi AK, Dwivedi A, Sankhwar P. MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer. Cancer Biol Med 2015;12:328-41. [PMID: 26779370 DOI: 10.7497/j.issn.2095-3941.2015.0024] [Cited by in F6Publishing: 44] [Reference Citation Analysis]
146 Dong J, Xu M. A 19‑miRNA Support Vector Machine classifier and a 6‑miRNA risk score system designed for ovarian cancer patients. Oncol Rep 2019;41:3233-43. [PMID: 31002358 DOI: 10.3892/or.2019.7108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
147 Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, Kundel Y, Brenner R, Morgenstern S, Halpern M, Rosenfeld N, Chajut A, Niv Y, Kushnir M. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 2011; 17(35): 3976-3985 [PMID: 22046085 DOI: 10.3748/wjg.v17.i35.3976] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 62] [Article Influence: 6.1] [Reference Citation Analysis]
148 Bockmeyer CL, Christgen M, Müller M, Fischer S, Ahrens P, Länger F, Kreipe H, Lehmann U. MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res Treat 2011;130:735-45. [PMID: 21409395 DOI: 10.1007/s10549-010-1303-3] [Cited by in Crossref: 88] [Cited by in F6Publishing: 90] [Article Influence: 8.0] [Reference Citation Analysis]
149 Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med 2011;15:1593-602. [PMID: 20716115 DOI: 10.1111/j.1582-4934.2010.01148.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 88] [Article Influence: 7.9] [Reference Citation Analysis]
150 Wang X, Han L, Zhou L, Wang L, Zhang LM. Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network. Oncol Rep 2018;40:2659-73. [PMID: 30226545 DOI: 10.3892/or.2018.6707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
151 Samuel P, Carter DR. The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma. Mol Diagn Ther 2017;21:59-73. [PMID: 27718164 DOI: 10.1007/s40291-016-0242-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
152 Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: From farm to pharmacy. BioFactors 2013;39:2-13. [DOI: 10.1002/biof.1079] [Cited by in Crossref: 225] [Cited by in F6Publishing: 206] [Article Influence: 25.0] [Reference Citation Analysis]
153 Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S, Zhang JD, Wiemann S, Sahin Ö. MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol. 2012;32:633-651. [PMID: 22144583 DOI: 10.1128/mcb.06212-11] [Cited by in Crossref: 157] [Cited by in F6Publishing: 102] [Article Influence: 14.3] [Reference Citation Analysis]
154 Castro FO, Sharbati S, Rodríguez-Alvarez LL, Cox JF, Hultschig C, Einspanier R. MicroRNA expression profiling of elongated cloned and in vitro-fertilized bovine embryos. Theriogenology 2010;73:71-85. [PMID: 19836069 DOI: 10.1016/j.theriogenology.2009.08.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
155 Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romualdi C, D'incalci M. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. The Lancet Oncology 2011;12:273-85. [DOI: 10.1016/s1470-2045(11)70012-2] [Cited by in Crossref: 142] [Cited by in F6Publishing: 84] [Article Influence: 12.9] [Reference Citation Analysis]
156 Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 2012;12:613-26. [DOI: 10.1038/nrc3318] [Cited by in Crossref: 344] [Cited by in F6Publishing: 345] [Article Influence: 34.4] [Reference Citation Analysis]
157 Lang Y, Xu S, Ma J, Wu J, Jin S, Cao S, Yu Y. MicroRNA-429 induces tumorigenesis of human non-small cell lung cancer cells and targets multiple tumor suppressor genes. Biochem Biophys Res Commun 2014;450:154-9. [PMID: 24866238 DOI: 10.1016/j.bbrc.2014.05.084] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
158 Rogers TJ, Christenson JL, Greene LI, O'Neill KI, Williams MM, Gordon MA, Nemkov T, D'Alessandro A, Degala GD, Shin J, Tan AC, Cittelly DM, Lambert JR, Richer JK. Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression. Mol Cancer Res 2019;17:30-41. [PMID: 30213797 DOI: 10.1158/1541-7786.MCR-18-0246] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
159 Sun Q, Zou X, Zhang T, Shen J, Yin Y, Xiang J. The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer. Gynecologic Oncology 2014;132:730-8. [DOI: 10.1016/j.ygyno.2014.01.047] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
160 Wang L, Zhu MJ, Ren AM, Wu HF, Han WM, Tan RY, Tu RQ. A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. PLoS One. 2014;9:e96472. [PMID: 24816756 DOI: 10.1371/journal.pone.0096472] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 7.3] [Reference Citation Analysis]
161 Nguyen VHL, Yue C, Du KY, Salem M, O'Brien J, Peng C. The Role of microRNAs in Epithelial Ovarian Cancer Metastasis. Int J Mol Sci 2020;21:E7093. [PMID: 32993038 DOI: 10.3390/ijms21197093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
162 Li Z, Liu H, Jin X, Lo L, Liu J. Expression profiles of microRNAs from lactating and non-lactating bovine mammary glands and identification of miRNA related to lactation. BMC Genomics 2012;13:731. [PMID: 23270386 DOI: 10.1186/1471-2164-13-731] [Cited by in Crossref: 89] [Cited by in F6Publishing: 81] [Article Influence: 8.9] [Reference Citation Analysis]
163 Chen Y, Zhang L. WITHDRAWN: MiR-200 family and cancer: Function, regulation and signaling. Surg Oncol 2014:S0960-7404(14)00010-3. [PMID: 24679605 DOI: 10.1016/j.suronc.2014.03.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
164 Gibbons DL, Rizvi ZH, Kurie JM. The Role of MicroRNAs in Lung Cancer Development, Progression, and Metastasis. In: Cho WC, editor. MicroRNAs in Cancer Translational Research. Dordrecht: Springer Netherlands; 2011. pp. 73-89. [DOI: 10.1007/978-94-007-0298-1_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
165 Frede J, Fraser SP, Oskay-özcelik G, Hong Y, Ioana Braicu E, Sehouli J, Gabra H, Djamgoz MB. Ovarian cancer: Ion channel and aquaporin expression as novel targets of clinical potential. European Journal of Cancer 2013;49:2331-44. [DOI: 10.1016/j.ejca.2013.03.016] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
166 Guo C, Zhao D, Zhang Q, Liu S, Sun MZ. miR-429 suppresses tumor migration and invasion by targeting CRKL in hepatocellular carcinoma via inhibiting Raf/MEK/ERK pathway and epithelial-mesenchymal transition. Sci Rep 2018;8:2375. [PMID: 29403024 DOI: 10.1038/s41598-018-20258-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
167 McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes. 2011;60:1314-1323. [PMID: 21357793 DOI: 10.2337/db10-1557] [Cited by in Crossref: 217] [Cited by in F6Publishing: 205] [Article Influence: 19.7] [Reference Citation Analysis]
168 Wu D, Niu X, Pan H, Zhou Y, Zhang Z, Qu P, Zhou J. Tumor-suppressing effects of microRNA-429 in human renal cell carcinoma via the downregulation of Sp1. Oncol Lett 2016;12:2906-11. [PMID: 27698878 DOI: 10.3892/ol.2016.4953] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
169 Xu Q, Sun Q, Zhang J, Yu J, Chen W, Zhang Z. Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer. Carcinogenesis 2013;34:539-49. [DOI: 10.1093/carcin/bgs374] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 7.5] [Reference Citation Analysis]
170 Llauradó M, Majem B, Altadill T, Lanau L, Castellví J, Sánchez-iglesias JL, Cabrera S, De la Torre J, Díaz-feijoo B, Pérez-benavente A, Colás E, Olivan M, Doll A, Alameda F, Matias-guiu X, Moreno-bueno G, Carey MS, Del Campo JM, Gil-moreno A, Reventós J, Rigau M. MicroRNAs as prognostic markers in ovarian cancer. Molecular and Cellular Endocrinology 2014;390:73-84. [DOI: 10.1016/j.mce.2014.03.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
171 Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK. Tumour angiogenesis regulation by the miR-200 family. Nat Commun 2013;4:2427. [PMID: 24018975 DOI: 10.1038/ncomms3427] [Cited by in Crossref: 251] [Cited by in F6Publishing: 242] [Article Influence: 31.4] [Reference Citation Analysis]
172 Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer? EMBO Rep. 2010;11:670-677. [PMID: 20706219 DOI: 10.1038/embor.2010.117] [Cited by in Crossref: 545] [Cited by in F6Publishing: 527] [Article Influence: 45.4] [Reference Citation Analysis]
173 Ayaz L, Çayan F, Balci Ş, Görür A, Akbayir S, Yıldırım Yaroğlu H, Doğruer Unal N, Tamer L. Circulating microRNA expression profiles in ovarian cancer. J Obstet Gynaecol 2014;34:620-4. [PMID: 24911418 DOI: 10.3109/01443615.2014.919998] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
174 Koutsaki M, Spandidos DA, Zaravinos A. Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics. Cancer Lett 2014;351:173-81. [PMID: 24952258 DOI: 10.1016/j.canlet.2014.05.022] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 9.9] [Reference Citation Analysis]
175 Liu X, Song B, Li S, Wang N, Yang H. Identification and functional analysis of the risk microRNAs associated with cerebral low-grade glioma prognosis. Mol Med Rep 2017;16:1173-9. [PMID: 28586047 DOI: 10.3892/mmr.2017.6705] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
176 Wise PM, Neviani P, Riwaldt S, Corydon TJ, Wehland M, Braun M, Krüger M, Infanger M, Grimm D. Changes in Exosomal miRNA Composition in Thyroid Cancer Cells after Prolonged Exposure to Real Microgravity in Space. Int J Mol Sci 2021;22:12841. [PMID: 34884646 DOI: 10.3390/ijms222312841] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Wang ZH, Xu CJ. Research Progress of MicroRNA in Early Detection of Ovarian Cancer. Chin Med J (Engl) 2015;128:3363-70. [PMID: 26668153 DOI: 10.4103/0366-6999.171459] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
178 Huang J, Hu W, Sood AK. Prognostic biomarkers in ovarian cancer. Cancer Biomark 2010-2011;8:231-51. [PMID: 22045356 DOI: 10.3233/CBM-2011-0212] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
179 Du Y, Liu Z, Gu L, Zhou J, Zhu BD, Ji J, Deng D. Characterization of human gastric carcinoma-related methylation of 9 miR CpG islands and repression of their expressions in vitro and in vivo. BMC Cancer. 2012;12:249. [PMID: 22703336 DOI: 10.1186/1471-2407-12-249] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
180 Feng B, Wang R, Chen LB. Review of miR-200b and cancer chemosensitivity. Biomed Pharmacother. 2012;66:397-402. [PMID: 22795796 DOI: 10.1016/j.biopha.2012.06.002] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
181 Lei Y, Chen L, Zhang G, Shan A, Ye C, Liang B, Sun J, Liao X, Zhu C, Chen Y, Wang J, Zhang E, Deng L. MicroRNAs target the Wnt/β‑catenin signaling pathway to regulate epithelial‑mesenchymal transition in cancer (Review). Oncol Rep 2020;44:1299-313. [PMID: 32700744 DOI: 10.3892/or.2020.7703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
182 Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, Wang TH, Lai CH. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene 2012;31:764-75. [PMID: 21725366 DOI: 10.1038/onc.2011.269] [Cited by in Crossref: 101] [Cited by in F6Publishing: 101] [Article Influence: 9.2] [Reference Citation Analysis]
183 Li J, Liang S, Yu H, Zhang J, Ma D, Lu X. An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. Gynecol Oncol 2010;119:543-8. [PMID: 20869762 DOI: 10.1016/j.ygyno.2010.08.034] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
184 Kumar V, Gupta S, Varma K, Sachan M. MicroRNA as Biomarker in Ovarian Cancer Management: Advantages and Challenges. DNA Cell Biol 2020. [PMID: 33156705 DOI: 10.1089/dna.2020.6024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 Katz B, Tropé CG, Reich R, Davidson B. MicroRNAs in Ovarian Cancer. Hum Pathol 2015;46:1245-56. [PMID: 26216350 DOI: 10.1016/j.humpath.2015.06.013] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
186 Ding M, Sun X, Zhong J, Zhang C, Tian Y, Ge J, Zhang C, Zen K, Wang J, Zhang C, Wang C. Decreased miR‐200a‐3p is a key regulator of renal carcinoma growth and migration by directly targeting CBL. J Cell Biochem 2018;119:9974-85. [DOI: 10.1002/jcb.27326] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
187 van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010;42:1282-90. [PMID: 20083225 DOI: 10.1016/j.biocel.2010.01.014] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 9.3] [Reference Citation Analysis]
188 Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol. 2011;223:102-115. [PMID: 21125669 DOI: 10.1002/path.2806] [Cited by in Crossref: 611] [Cited by in F6Publishing: 610] [Article Influence: 50.9] [Reference Citation Analysis]
189 Seifoleslami M, Khameneie MK, Mashayekhi F, Sedaghati F, Ziari K, Mansouri K, Safari A. RETRACTED ARTICLE: Identification of microRNAs (miR-203/miR-7) as potential markers for the early detection of lymph node metastases in patients with cervical cancer. Tumour Biol 2015. [PMID: 26490989 DOI: 10.1007/s13277-015-4265-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
190 Chen H, Xia B, Liu T, Lin M, Lou G. KIAA0101, a target gene of miR-429, enhances migration and chemoresistance of epithelial ovarian cancer cells. Cancer Cell Int 2016;16:74. [PMID: 27708548 DOI: 10.1186/s12935-016-0353-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
191 Zhang L, Jamaluddin MS, Weakley SM, Yao Q, Chen C. Roles and mechanisms of microRNAs in pancreatic cancer. World J Surg 2011;35:1725-31. [PMID: 21222121 DOI: 10.1007/s00268-010-0952-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
192 Wang Z, Li Y, Kong D, Ahmad A, Banerjee S, Sarkar FH. Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett 2010;292:141-8. [PMID: 20022691 DOI: 10.1016/j.canlet.2009.11.012] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 6.5] [Reference Citation Analysis]
193 Li Z, Chen B, Feng M, Ouyang H, Zheng M, Ye Q, Nie Q, Zhang X. MicroRNA-23b Promotes Avian Leukosis Virus Subgroup J (ALV-J) Replication by Targeting IRF1. Sci Rep 2015;5:10294. [PMID: 25980475 DOI: 10.1038/srep10294] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
194 Imanaka Y, Tsuchiya S, Sato F, Shimada Y, Shimizu K, Tsujimoto G. MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet 2011;56:270-6. [DOI: 10.1038/jhg.2011.1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 5.7] [Reference Citation Analysis]
195 Wang L, Chen J, Lu C. Circular RNA Foxo3 enhances progression of ovarian carcinoma cells. Aging (Albany NY) 2021;13:22432-43. [PMID: 34555810 DOI: 10.18632/aging.203550] [Reference Citation Analysis]
196 Marimuthu A, Huang T, Selvan LDN, Renuse S, Nirujogi RS, Kumar P, Pinto SM, Rajagopalan S, Pandey A, Harsha H, Chatterjee A. Identification of targets of miR-200b by a SILAC-based quantitative proteomic approach. EuPA Open Proteomics 2014;4:10-7. [DOI: 10.1016/j.euprot.2014.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
197 Hui A, How C, Ito E, Liu FF. Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer 2011;11:500. [PMID: 22128797 DOI: 10.1186/1471-2407-11-500] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
198 Wang T, Zang WQ, Li M, Wang N, Zheng YL, Zhao GQ. Effect of miR-451 on the biological behavior of the esophageal carcinoma cell line EC9706. Dig Dis Sci. 2013;58:706-714. [PMID: 23053883 DOI: 10.1007/s10620-012-2395-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
199 Dahiya N, Morin PJ. MicroRNAs in ovarian carcinomas. Endocr Relat Cancer 2010;17:F77-89. [PMID: 19903743 DOI: 10.1677/ERC-09-0203] [Cited by in Crossref: 70] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
200 Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW, Ahn WS. Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014;8:293-314. [PMID: 24591819 DOI: 10.2147/DDDT.S51969] [Cited by in Crossref: 16] [Cited by in F6Publishing: 51] [Article Influence: 2.0] [Reference Citation Analysis]
201 Chuang TD, Khorram O. Regulation of Cell Cycle Regulatory Proteins by MicroRNAs in Uterine Leiomyoma. Reprod Sci 2019;26:250-8. [PMID: 29642801 DOI: 10.1177/1933719118768692] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
202 Mandilaras V, Vernon M, Meryet-figuière M, Karakasis K, Lambert B, Poulain L, Oza A, Denoyelle C, Lheureux S. Updates and current challenges in microRNA research for personalized medicine in ovarian cancer. Expert Opinion on Biological Therapy 2017;17:927-43. [DOI: 10.1080/14712598.2017.1340935] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
203 Wiemer EAC. Stressed tumor cell, chemosensitized cancer. Nat Med 2011;17:1552-4. [DOI: 10.1038/nm.2593] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
204 Aguilar-Gallardo C, Rutledge EC, Martínez-Arroyo AM, Hidalgo JJ, Domingo S, Simón C. Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. Stem Cell Rev Rep 2012;8:994-1010. [PMID: 22278130 DOI: 10.1007/s12015-011-9344-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
205 Kan CW, Hahn MA, Gard GB, Maidens J, Huh JY, Marsh DJ, Howell VM. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer 2012;12:627. [PMID: 23272653 DOI: 10.1186/1471-2407-12-627] [Cited by in Crossref: 119] [Cited by in F6Publishing: 120] [Article Influence: 11.9] [Reference Citation Analysis]
206 Szajnik M, Czystowska-Kuźmicz M, Elishaev E, Whiteside TL. Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Rev Mol Diagn 2016;16:811-26. [PMID: 27268121 DOI: 10.1080/14737159.2016.1194758] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]